An Improvement in the Supply of Safe Blood: Virus Inactivated Plasma Prepared in the Blood Bank

  • Y. Piquet
  • G. Janvier
  • P. Selosse
  • E. Angevain
  • J. Jouneau
  • G. Nicolle
  • C. Doutremepuich
  • G. Vezon
Part of the Developments in Hematology and Immunology book series (DIHI, volume 27)


To reduce virus infectivity in blood products, several methods were attempted. Selection and then screening of volunteer donors (HBsAg, anti-HIV Ab, anti-HBc Ab, anti-HCV Ab, ALAT) have reduced the likelihood of viral transmission. Despite all the screening tests and the purification methods used to produce therapeutic stable protein solutions, the best method for further reducing viral risks is the introduction of a viral inactivation step in the procedure. For albumin, pasteurization [[1]] on the final product has been found to be an effective way for viral sterilization and until now no case of hepatitis B has been attributed to pasteurized albumin. For coagulation factors, the first method used was the heating of concentrates in the lyophilised state [[2]] to kill HIV virus. Improvement has been achieved by including a solvent detergent method in the procedure to inactivate all viruses [[3]].


Human Immunodeficiency Virus Factor VIII Coagulation Factor Virus Inactivation Lyophilised State 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gellis S, Neefe J, Strong l, Janeway C, Scatchard G. Chemical, clinical and immunological studies on products of human plasma fractionation: Inactivation of virus of homologous serum albumin by means of heat. J Clin Invest 1948;27:239–44.CrossRefGoogle Scholar
  2. 2.
    Hollinger JB, Dolano G, Thomas W, Gyorkey F. Reduction risk of hepatitis transmission by heat treatment of a human factor VIII concentrate. J Inf Dis 1984;150:250–64.CrossRefGoogle Scholar
  3. 3.
    Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of virus in labile blood derivates. I. Disruption of lipid-enveloped virus by tri/n/buthyl/phosphate detergent combinations. Transfusion 1985;25:216–9.Google Scholar
  4. 4.
    Horowitz B. Virus sterilization of plasma protein by treatment with solvent detergent mixtures. A summary. Thromb Res 1987;48(supp.VII):51 (abstract).CrossRefGoogle Scholar
  5. 5.
    Biggs R, Evelin S, Richards G. The assay of anti-haemophilic globulin activity. Br J Haemat 1955;1:20–34.CrossRefGoogle Scholar
  6. 6.
    Soulier JP, Larrieu MS. Etude analytique des temps de Quick allongés. Dosage de prothrombine, de proconvertine et de pro-accélérine. Sang 1982;23:549–59.Google Scholar
  7. 7.
    Odegard OR, Lie M, Abilgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975;6:287–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Howard MA, Firkin BG. Ristocetin: A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971;26:362–9.PubMedGoogle Scholar
  9. 9.
    Clauss A. Gerinnungs physiologische Schnellmethode 2 in Bestimmung des Fibrinogens. Acta Haemat 1975;17:237–46.CrossRefGoogle Scholar
  10. 10.
    Vinazzer H. Comparison between two concentrates with factor VIII inhibitor bypassing activity. Thromb Res 1982;26:21–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Martinoli JL, Doussin G, Nigham F. Automatisation de l’étude de l’hémostase et de la fibrinolyse par les substrats chromogéniques. Nouv Rev Franç Hématol 1981;23(supp.):L (abstract Proc. VIe CSFG, Avignon).Google Scholar
  12. 12.
    Kingdon HS, Lundblad ML, Veltkamp JJ, Amonson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975;33:617–31.PubMedGoogle Scholar
  13. 13.
    Wessler S, Reiner S, Sheps MC. Biological assay of a thrombosis inducing activity in human serum. J Appl Phys 1959;14:943–53.Google Scholar
  14. 14.
    Gornall A, Bardawill CH, David M. Determination of serum protein by means of the biuret reaction. J Biol Chem 1949;177:751–66.PubMedGoogle Scholar
  15. 15.
    Elson EC, Ivor L, Gochman N. Substitution of a non hazardous chromogen for benzidine in the measurement of plasma haemoglobin. Am J Clin Path 1978;69:354.PubMedGoogle Scholar
  16. 16.
    Thomas LLM, Sturck A, Kahle LH, ten Cate JW. Quantitative endotoxin determination in blood with a chromogenic substrate. Clin Chem 1981;116:63–8.CrossRefGoogle Scholar
  17. 17.
    International Forum. What are the critical factors in the production and quality control of frozen plasma intended for direct transfusion or for fractionation to provide medically needed labile coagulation factors? Vox Sang 1983;44:246–59.CrossRefGoogle Scholar
  18. 18.
    Carlebjork G, Blombäck M, Pihlstedt P. Freezing of plasma and recovery of factor VIII. Transfusion 1986;26/2:159–62PubMedCrossRefGoogle Scholar
  19. 19.
    Prodouz KN, Fratantoni JC, Boone EJ, Booner RF. Use of laser UV for inactivation of virus in blood products. Blood 1987;70:589–92.PubMedGoogle Scholar
  20. 20.
    Mathews JL, Newman JT, Sogandares-Bernal F, et al. Photodynamic therapy of viral contaminants with potential for blood banking application. Transfusion 1988;28:80–3.CrossRefGoogle Scholar
  21. 21.
    Yoshiaki H, Shinsi H, Sumunu K, et al. A novel method for removal of human immunodeficiency virus: Filtration with porous polymeric membranes. Vox Sang 1989;56:230–6.CrossRefGoogle Scholar
  22. 22.
    Hiemstra H, Tersmette M, Vos H, Over J, van Berkel MP, Debree H. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors. Transfusion 1991;31:32–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Horowitz B, Piet PJ, Prince AM, Edwards CA, Lippin A, Walakovits ML. Inactivation of lipid enveloped viruses in labile blood derivates by unsaturted fatty acids. Vox Sang 1988;54:14–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Piet MPJ, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri-n-butyl phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma’s subsequent fractionation. Transfusion 1990;30:591–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Horowitz B, Chin S, Prince AM, Brotman B, Pascual D, Williams B. Preparation and characterization of S/D-FFP, a virus sterilized “fresh frozen plasma”. Thromb Haem 1991;65:1163 (abstract).Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • Y. Piquet
    • 1
  • G. Janvier
    • 2
  • P. Selosse
    • 3
  • E. Angevain
    • 1
  • J. Jouneau
    • 1
  • G. Nicolle
    • 1
  • C. Doutremepuich
    • 4
  • G. Vezon
    • 1
  1. 1.Centre Régional de Transfusion SanguineBordeaux CedexFrance
  2. 2.CHU PellegrinBordeauxFrance
  3. 3.Octapharma A.G.GlarusSwitzerland
  4. 4.Facult de Pharmacie de BordeauxBordeauxFrance

Personalised recommendations